Alex Carchidi
Alex began writing for the Fool in early 2020 and follows companies in the healthcare sector. Formerly a researcher in the biotech industry, he leverages his science background in his work as a writer and entrepreneur. His interests include exploring his hometown of Boston, traveling in Latin America, and value investing.
Recent Articles by Alex Carchidi
Down 19% in 1 Day, Is Novo Nordisk Stock Still a Buy?
Is Merck the Next Big Weight Loss Stock?
Is AbbVie Stock a Buy?
1 big new Green Flag for CRISPR Therapeutics' Stock
Could Tilray Brands Be The Next Hims & Hers Health?
Is Pfizer a Millionaire-Maker?
Is Teladoc Health Stock a Buy?
Where Will Teladoc Health Be in 3 Years?
Is Bristol-Myers Squibb Stock a Millionaire Maker?
Is Medical Properties Trust Stock a Buy?
Warning: This Skyrocketing Stock Has a Hidden Risk
HOW THE MOTLEY FOOL CAN HELP YOU
-
Premium Investing Guidance
Market beating stocks from our award-winning service
-
The Daily Upside Newsletter
Investment news and high-quality insights delivered straight to your inbox
-
Get Started Investing
You can do it. Successful investing in just a few steps
-
Win at Retirement
Secrets and strategies for the post-work life you want.
-
Find a Broker
Find the right brokerage account for you.
-
Listen to our Podcasts
Hear our experts take on stocks, the market, and how to invest.
Motley Fool Returns
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.